Health Care & Life Sciences » Pharmaceuticals | Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
-
-
467.00
1,085.00
2,038
Cost of Goods Sold (COGS) incl. D&A
4.00
9.00
50.00
-
-
-
Gross Income
4.00
9.00
50.00
-
-
-
SG&A Expense
14,558.00
9,133.00
10,825.00
17,180.00
13,210.00
12,366
EBIT
14,562.00
9,142.00
10,875.00
16,882.00
12,364.00
10,715
Non Operating Income/Expense
10.00
-
-
-
-
25
Interest Expense
2,912.00
-
-
-
-
-
Pretax Income
17,484.00
9,102.00
10,622.00
16,847.00
12,299.00
9,781
Income Tax
1.00
1.00
-
106.00
-
75
Consolidated Net Income
17,485.00
9,103.00
10,622.00
16,953.00
12,299.00
9,856
Net Income
17,485.00
9,103.00
10,622.00
16,953.00
12,299.00
9,856
Net Income After Extraordinaries
17,485.00
9,103.00
10,622.00
16,953.00
12,299.00
9,856
Net Income Available to Common
17,485.00
9,103.00
10,622.00
16,953.00
12,299.00
9,856
EPS (Basic)
1.58
0.88
0.96
1.49
0.98
0.54
Basic Shares Outstanding
11,100.50
10,323.70
11,100.50
11,374.70
12,487.30
18,137.70
EPS (Diluted)
1.58
0.88
0.96
1.49
0.98
0.54
Diluted Shares Outstanding
11,100.50
10,323.70
11,100.50
11,374.70
12,487.30
18,137.70
EBITDA
14,558.00
9,133.00
10,825.00
16,713.00
12,125.00
10,328
Non-Operating Interest Income
-
40.00
253.00
35.00
65.00
959

About Galmed Pharmaceuticals

View Profile
Address
16 Zeev Tiomkin Street
Tel Aviv TA 6578317
Israel
Employees -
Website http://www.galmedpharma.com
Updated 07/08/2019
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on the development of the liver targeted stearoyl-coenzyme A desaturase-1 modulator Aramchol, novel, once-daily, oral therapy for the treatment of NASH for variable populations, as well as other liver associated disorders. The Aramchol is a synthetic conjugate of cholic acid, or a type of bile acid, and arachidic acid, or a type of saturated fatty acid, both of which, in their non-synthetic forms, are naturally occurring.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.